TWI736578B - 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 - Google Patents
6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 Download PDFInfo
- Publication number
- TWI736578B TWI736578B TW106103864A TW106103864A TWI736578B TW I736578 B TWI736578 B TW I736578B TW 106103864 A TW106103864 A TW 106103864A TW 106103864 A TW106103864 A TW 106103864A TW I736578 B TWI736578 B TW I736578B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- pyridin
- amine
- alkyl
- isopropyl
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 188
- 150000003839 salts Chemical class 0.000 claims abstract description 86
- 239000003814 drug Substances 0.000 claims abstract description 42
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 claims abstract description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 226
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 81
- 125000001072 heteroaryl group Chemical group 0.000 claims description 67
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- WXXDYJWVVZUDKA-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1CCN(CC1)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F WXXDYJWVVZUDKA-UHFFFAOYSA-N 0.000 claims description 3
- NZJMHSTXIXCELC-OAQYLSRUSA-N N-[5-[[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C[C@@H]2N(CC1)CCC2)C=1C=C2C(=NC=1)N=C(N2C(C)C)C NZJMHSTXIXCELC-OAQYLSRUSA-N 0.000 claims description 3
- MLXKGRKGLLBNRE-FQEVSTJZSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoro-N-[5-[[(3S)-3-(methoxymethyl)-4-methylpiperazin-1-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H](N(CC1)C)COC)C MLXKGRKGLLBNRE-FQEVSTJZSA-N 0.000 claims description 2
- RHXRAKXKHNWBSI-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-N-[5-[(3-ethyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)CC)C RHXRAKXKHNWBSI-UHFFFAOYSA-N 0.000 claims description 2
- LXWBWBJMRYBYLJ-UHFFFAOYSA-N N-[4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoropyrimidin-2-yl]-6-ethyl-7,8-dihydro-5H-1,6-naphthyridin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=2CCN(CC=2C=C1)CC)C LXWBWBJMRYBYLJ-UHFFFAOYSA-N 0.000 claims description 2
- NZJMHSTXIXCELC-NRFANRHFSA-N N-[5-[[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C[C@H]2N(CC1)CCC2)C=1C=C2C(=NC=1)N=C(N2C(C)C)C NZJMHSTXIXCELC-NRFANRHFSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- UPCPDAQDMQXBSS-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-N-[5-[(8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CC2CCC(C1)N2CC)C UPCPDAQDMQXBSS-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 49
- 201000010099 disease Diseases 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002062 proliferating effect Effects 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- -1 2-methylbutenyl Chemical group 0.000 description 156
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 111
- 125000000623 heterocyclic group Chemical group 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 82
- 239000000203 mixture Substances 0.000 description 76
- 125000003118 aryl group Chemical group 0.000 description 71
- 125000000304 alkynyl group Chemical group 0.000 description 60
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 48
- 239000000543 intermediate Substances 0.000 description 46
- 239000000243 solution Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 43
- 125000000753 cycloalkyl group Chemical group 0.000 description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 35
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 125000003545 alkoxy group Chemical group 0.000 description 31
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- 125000003342 alkenyl group Chemical group 0.000 description 28
- 125000004414 alkyl thio group Chemical group 0.000 description 28
- 125000000000 cycloalkoxy group Chemical group 0.000 description 28
- 125000005366 cycloalkylthio group Chemical group 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- 150000002431 hydrogen Chemical class 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 125000003282 alkyl amino group Chemical group 0.000 description 26
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 26
- 239000011734 sodium Substances 0.000 description 26
- 229910052717 sulfur Inorganic materials 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 125000004429 atom Chemical group 0.000 description 19
- 125000005842 heteroatom Chemical group 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 229910052799 carbon Inorganic materials 0.000 description 18
- 239000003480 eluent Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 238000001308 synthesis method Methods 0.000 description 16
- UOIMSYSBTIGWJJ-UHFFFAOYSA-N tert-butyl 4-[(6-aminopyridin-3-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(N)N=C1 UOIMSYSBTIGWJJ-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000011593 sulfur Chemical group 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 238000010189 synthetic method Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 8
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- NJSKBCIZXYIRPY-UHFFFAOYSA-N (1-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)boronic acid Chemical compound C(C)(C)C1=NN(C2=NC=C(C=C21)B(O)O)C NJSKBCIZXYIRPY-UHFFFAOYSA-N 0.000 description 7
- IJQYADFIFAUUFR-UHFFFAOYSA-N 1-(5-bromo-2-chloropyridin-3-yl)-2-methylpropan-1-one Chemical compound BrC=1C=C(C(=NC=1)Cl)C(C(C)C)=O IJQYADFIFAUUFR-UHFFFAOYSA-N 0.000 description 7
- YGPYNLZCNDPHTQ-UHFFFAOYSA-N 5-bromo-2-chloropyridine-3-carbaldehyde Chemical compound ClC1=NC=C(Br)C=C1C=O YGPYNLZCNDPHTQ-UHFFFAOYSA-N 0.000 description 7
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- QLXASFJHUCKEHU-UHFFFAOYSA-N 5-bromo-3-fluoropyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1F QLXASFJHUCKEHU-UHFFFAOYSA-N 0.000 description 6
- XDCYRPFADMZSFI-UHFFFAOYSA-N 5-bromo-3-tert-butyl-2H-pyrazolo[3,4-b]pyridine Chemical compound BrC=1C=C2C(=NC=1)NN=C2C(C)(C)C XDCYRPFADMZSFI-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 6
- 150000001335 aliphatic alkanes Chemical group 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 229920001223 polyethylene glycol Chemical class 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- QRCIVOIEHSUADI-UHFFFAOYSA-N tert-butyl 4-[(6-bromopyridin-3-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(Br)N=C1 QRCIVOIEHSUADI-UHFFFAOYSA-N 0.000 description 6
- OMJCJJZDACYWCU-UHFFFAOYSA-N (3-propan-2-yl-2H-pyrazolo[3,4-b]pyridin-5-yl)boronic acid Chemical compound C(C)(C)C1=NNC2=NC=C(C=C21)B(O)O OMJCJJZDACYWCU-UHFFFAOYSA-N 0.000 description 5
- OWOHLURDBZHNGG-YFKPBYRVSA-N (8ar)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)[C@@H]2CCCN12 OWOHLURDBZHNGG-YFKPBYRVSA-N 0.000 description 5
- XCYSMZLJIAGUFC-UHFFFAOYSA-N 1-(5-bromo-2-chloropyridin-3-yl)-2,2-dimethylpropan-1-one Chemical compound BrC=1C=C(C(=NC=1)Cl)C(C(C)(C)C)=O XCYSMZLJIAGUFC-UHFFFAOYSA-N 0.000 description 5
- GXEGGTKFWNXZPI-UHFFFAOYSA-N 1-(5-bromo-2-chloropyridin-3-yl)-2-methylpropan-1-ol Chemical compound BrC=1C=C(C(=NC=1)Cl)C(C(C)C)O GXEGGTKFWNXZPI-UHFFFAOYSA-N 0.000 description 5
- MNJBMPQTXVZMFZ-UHFFFAOYSA-N 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1CN(CC)CCN1CC1=CC=C(N)N=C1 MNJBMPQTXVZMFZ-UHFFFAOYSA-N 0.000 description 5
- FDTXFVXXVRRKFM-UHFFFAOYSA-N 5-bromo-N-tert-butyl-2-nitropyridin-3-amine Chemical compound BrC=1C=C(C(=NC=1)[N+](=O)[O-])NC(C)(C)C FDTXFVXXVRRKFM-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001204 N-oxides Chemical class 0.000 description 5
- 239000002202 Polyethylene glycol Chemical class 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 5
- PNFFICVZQREJQA-UHFFFAOYSA-N tert-butyl 4-[[6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazine-1-carboxylate Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)CN1CCN(CC1)C(=O)OC(C)(C)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C PNFFICVZQREJQA-UHFFFAOYSA-N 0.000 description 5
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 4
- ZZGSPGXWLOYKFH-UHFFFAOYSA-N (5-bromo-2-chloropyridin-3-yl)methanol Chemical compound OCC1=CC(Br)=CN=C1Cl ZZGSPGXWLOYKFH-UHFFFAOYSA-N 0.000 description 4
- FTTATHOUSOIFOQ-ZETCQYMHSA-N (8as)-1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCC[C@H]21 FTTATHOUSOIFOQ-ZETCQYMHSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 4
- GAIXRSXIEKWQOT-UHFFFAOYSA-N 5-(2-chloro-5-fluoropyrimidin-4-yl)-1-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridine Chemical compound ClC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N(N=C2C(C)C)C)F GAIXRSXIEKWQOT-UHFFFAOYSA-N 0.000 description 4
- UZEOLJJBRRWSCG-UHFFFAOYSA-N 5-(2-chloro-5-fluoropyrimidin-4-yl)-7-fluoro-1-methyl-3-propan-2-yl-3a,7a-dihydroindazole Chemical compound ClC1=NC=C(C(=N1)C1=CC2C(=NN(C2C(=C1)F)C)C(C)C)F UZEOLJJBRRWSCG-UHFFFAOYSA-N 0.000 description 4
- TTZIIUFYHSVXOO-UHFFFAOYSA-N 5-bromo-1-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridine Chemical compound C1=C(Br)C=C2C(C(C)C)=NN(C)C2=N1 TTZIIUFYHSVXOO-UHFFFAOYSA-N 0.000 description 4
- MRHGOTPAKCWLTL-UHFFFAOYSA-N 5-bromo-2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridine Chemical compound N1=CC(Br)=CC2=C(C(C)C)N(C)N=C21 MRHGOTPAKCWLTL-UHFFFAOYSA-N 0.000 description 4
- JZTXKNVJIAEOFL-UHFFFAOYSA-N 5-bromo-3-N-tert-butylpyridine-2,3-diamine Chemical compound BrC=1C=C(C(=NC=1)N)NC(C)(C)C JZTXKNVJIAEOFL-UHFFFAOYSA-N 0.000 description 4
- YMXQSNGTVXQMLC-UHFFFAOYSA-N 5-bromo-3-fluoro-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=C(Br)C=C1F YMXQSNGTVXQMLC-UHFFFAOYSA-N 0.000 description 4
- XWYBLYSOXIQCEC-UHFFFAOYSA-N 5-bromo-3-tert-butyl-2-methylpyrazolo[3,4-b]pyridine Chemical compound N1=CC(Br)=CC2=C(C(C)(C)C)N(C)N=C21 XWYBLYSOXIQCEC-UHFFFAOYSA-N 0.000 description 4
- GVXZNRJLWSJQMZ-UHFFFAOYSA-N BrC=1C=C2C(=NC1)NN=C2C(C)C Chemical compound BrC=1C=C2C(=NC1)NN=C2C(C)C GVXZNRJLWSJQMZ-UHFFFAOYSA-N 0.000 description 4
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- ZHUNQQHNUGVFKA-UWVGGRQHSA-N (1S,4S)-2-[(6-bromopyridin-3-yl)methyl]-2,5-diazabicyclo[2.2.1]heptane Chemical compound BrC1=CC=C(C=N1)CN1[C@@H]2CN[C@H](C1)C2 ZHUNQQHNUGVFKA-UWVGGRQHSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CKULKERWFSGWHM-UHFFFAOYSA-N 1-(5-bromo-2-chloropyridin-3-yl)-2,2-dimethylpropan-1-ol Chemical compound BrC=1C=C(C(=NC=1)Cl)C(C(C)(C)C)O CKULKERWFSGWHM-UHFFFAOYSA-N 0.000 description 3
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- MMQCTXWUZNJUTF-UHFFFAOYSA-N 5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-amine Chemical compound C1CN(C)CCN1CC1=CC=C(N)N=C1 MMQCTXWUZNJUTF-UHFFFAOYSA-N 0.000 description 3
- LEDIWMKGVIKUJE-RYUDHWBXSA-N 5-[[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]pyridin-2-amine Chemical compound C(C)N1[C@@H]2CN([C@H](C1)C2)CC=1C=CC(=NC=1)N LEDIWMKGVIKUJE-RYUDHWBXSA-N 0.000 description 3
- IHHHPMVCOOADKN-QWRGUYRKSA-N 5-[[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]pyridin-2-amine Chemical compound CN1[C@@H]2CN([C@H](C1)C2)CC=1C=CC(=NC=1)N IHHHPMVCOOADKN-QWRGUYRKSA-N 0.000 description 3
- QBNKJVGTABFRDK-GFCCVEGCSA-N 5-[[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]pyridin-2-amine Chemical compound C1[C@@H]2N(CCN1CC=1C=CC(=NC=1)N)CCC2 QBNKJVGTABFRDK-GFCCVEGCSA-N 0.000 description 3
- QBNKJVGTABFRDK-LBPRGKRZSA-N 5-[[(8aS)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]pyridin-2-amine Chemical compound C1[C@H]2N(CCN1CC=1C=CC(=NC=1)N)CCC2 QBNKJVGTABFRDK-LBPRGKRZSA-N 0.000 description 3
- NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 description 3
- UIWVEKSONRSDAP-UHFFFAOYSA-N 6-bromo-1-tert-butyl-2-methylimidazo[4,5-b]pyridine Chemical compound BrC=1C=C2C(=NC=1)N=C(N2C(C)(C)C)C UIWVEKSONRSDAP-UHFFFAOYSA-N 0.000 description 3
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- VCLLGSYJTJIQGM-STQMWFEESA-N NC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C Chemical compound NC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C VCLLGSYJTJIQGM-STQMWFEESA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- OWOHLURDBZHNGG-UHFFFAOYSA-N cyclo-Gly-L-Pro Natural products O=C1CNC(=O)C2CCCN12 OWOHLURDBZHNGG-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910052698 phosphorus Chemical group 0.000 description 3
- 239000011574 phosphorus Chemical group 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- QOMIQLRRGXOCAO-STQMWFEESA-N tert-butyl (1S,4S)-5-[(6-bromopyridin-3-yl)methyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound BrC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C QOMIQLRRGXOCAO-STQMWFEESA-N 0.000 description 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- ZREYCSQQCSFFDH-UHFFFAOYSA-N tributyl-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)stannane Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)[Sn](CCCC)(CCCC)CCCC)C ZREYCSQQCSFFDH-UHFFFAOYSA-N 0.000 description 3
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- APZCGKAVHWAPFS-QWRGUYRKSA-N (1S,4S)-2-[(6-bromopyridin-3-yl)methyl]-5-methyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound BrC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)C APZCGKAVHWAPFS-QWRGUYRKSA-N 0.000 description 2
- CPTKWEIJBBDEJS-LBPRGKRZSA-N (8aS)-2-[(6-bromopyridin-3-yl)methyl]-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine Chemical compound BrC1=CC=C(C=N1)CN1C[C@H]2N(CC1)CCC2 CPTKWEIJBBDEJS-LBPRGKRZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- JWWUDSUSOPKRRA-UHFFFAOYSA-N 5-bromo-3-N-propan-2-ylpyridine-2,3-diamine Chemical compound BrC=1C=C(C(=NC=1)N)NC(C)C JWWUDSUSOPKRRA-UHFFFAOYSA-N 0.000 description 2
- IEGVJMQVMUGLMP-UHFFFAOYSA-N 5-fluoro-N-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CCN(CC1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C IEGVJMQVMUGLMP-UHFFFAOYSA-N 0.000 description 2
- QCVASANWTXPRKW-UHFFFAOYSA-N 5-fluoro-N-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CCN(CC1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C QCVASANWTXPRKW-UHFFFAOYSA-N 0.000 description 2
- KZSRXRACNDDUOO-UHFFFAOYSA-N 6-(2-chloro-5-fluoropyrimidin-4-yl)-2-methyl-1-propan-2-ylimidazo[4,5-b]pyridine Chemical compound ClC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F KZSRXRACNDDUOO-UHFFFAOYSA-N 0.000 description 2
- OGNIIZLVRXUALR-UHFFFAOYSA-N 6-bromo-2-methyl-1-propan-2-ylimidazo[4,5-b]pyridine Chemical compound BrC=1C=C2C(=NC=1)N=C(N2C(C)C)C OGNIIZLVRXUALR-UHFFFAOYSA-N 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KLFAIAHJLSEKFM-UHFFFAOYSA-N CC1=NC2=C(N1C(C)C)C=C(C=N2)C3=NC(=NC=C3F)NC4=NC=C(C=C4)CN5CC=NC=C5 Chemical compound CC1=NC2=C(N1C(C)C)C=C(C=N2)C3=NC(=NC=C3F)NC4=NC=C(C=C4)CN5CC=NC=C5 KLFAIAHJLSEKFM-UHFFFAOYSA-N 0.000 description 2
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- YEXAQVXBDYXGKW-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1CCN(CC1)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F YEXAQVXBDYXGKW-UHFFFAOYSA-N 0.000 description 2
- KCRHHWXFYIFFII-OALUTQOASA-N N-[5-[[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound CC(C)n1c(C)nc2ncc(cc12)-c1nc(Nc2ccc(CN3C[C@@H]4C[C@H]3CN4)cn2)ncc1F KCRHHWXFYIFFII-OALUTQOASA-N 0.000 description 2
- ZVQATGQZELGFKO-SFTDATJTSA-N N-[5-[[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1[C@@H]2CN([C@H](C1)C2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F ZVQATGQZELGFKO-SFTDATJTSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000002009 alkene group Chemical group 0.000 description 2
- 125000002355 alkine group Chemical group 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- DXSUJCOMYMAJNG-AWEZNQCLSA-N benzyl (8as)-3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazine-2-carboxylate Chemical compound C([C@@H]1CCCN1CC1)N1C(=O)OCC1=CC=CC=C1 DXSUJCOMYMAJNG-AWEZNQCLSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GPAPAPSPVTYEKO-UHFFFAOYSA-N tributyl-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)stannane Chemical compound C(CCC)[Sn](C=1C=C2C(=NC=1)N=C(N2C(C)C)C)(CCCC)CCCC GPAPAPSPVTYEKO-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- JDKNINBDEDWGRT-RYUDHWBXSA-N (1S,4S)-2-[(6-bromopyridin-3-yl)methyl]-5-ethyl-2,5-diazabicyclo[2.2.1]heptane Chemical compound BrC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)CC JDKNINBDEDWGRT-RYUDHWBXSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- LGFQMLCQCHXACZ-UHFFFAOYSA-N (2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C(C)N1CC2C(C1)CN(C2)C(=O)C=1C=NC(=CC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F LGFQMLCQCHXACZ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VHYHRNYPVNFGNR-UHFFFAOYSA-N (3,5-ditert-butylphenyl)methanol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1 VHYHRNYPVNFGNR-UHFFFAOYSA-N 0.000 description 1
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- DOUFFRZIRGUHTC-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C(C)N1CCN(CC1)C(=O)C=1C=NC(=CC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F DOUFFRZIRGUHTC-UHFFFAOYSA-N 0.000 description 1
- CMMYBYKPLXALCJ-UHFFFAOYSA-N (8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-[6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C(C)N1C2CN(CC1CC2)C(=O)C=1C=NC(=CC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F CMMYBYKPLXALCJ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DZKRDHLYQRTDBU-UPHRSURJSA-N (z)-but-2-enediperoxoic acid Chemical compound OOC(=O)\C=C/C(=O)OO DZKRDHLYQRTDBU-UPHRSURJSA-N 0.000 description 1
- IIGCYQPNZRSCLY-UHFFFAOYSA-N 1,1-dimethyl-3-prop-1-enylurea Chemical compound CC=CNC(=O)N(C)C IIGCYQPNZRSCLY-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
- FIBQTVPCVMDBRJ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl-[6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CNCC2C1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C FIBQTVPCVMDBRJ-UHFFFAOYSA-N 0.000 description 1
- SVNBUGZPKYWXJJ-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-yl-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CNCC2C1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C SVNBUGZPKYWXJJ-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- JKIFPWHZEZQCQA-UHFFFAOYSA-N 2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=CC=C1S JKIFPWHZEZQCQA-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- ZVMLJQKAIDIPRT-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octan-3-yl-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C12CN(CC(CC1)N2)C(=O)C=1C=NC(=CC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F ZVMLJQKAIDIPRT-UHFFFAOYSA-N 0.000 description 1
- FVOSRKUKMOVUEY-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octan-8-yl-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methanone Chemical compound C12CNCC(CC1)N2C(=O)C=1C=NC(=CC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F FVOSRKUKMOVUEY-UHFFFAOYSA-N 0.000 description 1
- LDZJKURBUHBPFD-UHFFFAOYSA-N 3-[4-[[6-[[4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoropyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]propanenitrile Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=CC=C(C=N1)CN1CCN(CC1)CCC#N)C LDZJKURBUHBPFD-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- WWEINXQNCAWBPD-UHFFFAOYSA-N 3-fluoropyridin-2-amine Chemical compound NC1=NC=CC=C1F WWEINXQNCAWBPD-UHFFFAOYSA-N 0.000 description 1
- LZRVQPGTFYGJTK-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-chloro-N-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1Cl)NC1=NC=C(C=C1)CN1CCN(CC1)C)C LZRVQPGTFYGJTK-UHFFFAOYSA-N 0.000 description 1
- VQNZVQWFSQQFLK-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)C)C VQNZVQWFSQQFLK-UHFFFAOYSA-N 0.000 description 1
- ICMVUFVRHXEATK-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)C)C ICMVUFVRHXEATK-UHFFFAOYSA-N 0.000 description 1
- PLVLTWOHVSRQFW-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CC2CCC(C1)N2C)C PLVLTWOHVSRQFW-UHFFFAOYSA-N 0.000 description 1
- GUXAIKSXEWLWLW-GOSISDBHSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[[(3R)-3-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H](N(CC1)C1COC1)C)C GUXAIKSXEWLWLW-GOSISDBHSA-N 0.000 description 1
- QPXVIEKFXBBRFH-NRFANRHFSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[[(3S)-3-(methoxymethyl)-4-methylpiperazin-1-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H](N(CC1)C)COC)C QPXVIEKFXBBRFH-NRFANRHFSA-N 0.000 description 1
- GUXAIKSXEWLWLW-SFHVURJKSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[[(3S)-3-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@@H](N(CC1)C1COC1)C)C GUXAIKSXEWLWLW-SFHVURJKSA-N 0.000 description 1
- LQCYWVTYFSAQBD-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-5-fluoro-N-[5-[[4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)C1COC1)C LQCYWVTYFSAQBD-UHFFFAOYSA-N 0.000 description 1
- YLPFCGWRMZTJTB-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-N-[5-(3,8-diazabicyclo[3.2.1]octan-8-ylmethyl)pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C12CNCC(CC1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)(C)C)C)F YLPFCGWRMZTJTB-UHFFFAOYSA-N 0.000 description 1
- HNWOSAHTHYQGNJ-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-N-[5-[(3-ethyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)CC)C HNWOSAHTHYQGNJ-UHFFFAOYSA-N 0.000 description 1
- JSNCGRMSIMEFBD-UHFFFAOYSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-N-[5-[1-(4-ethylpiperazin-1-yl)ethyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)C(C)N1CCN(CC1)CC)C JSNCGRMSIMEFBD-UHFFFAOYSA-N 0.000 description 1
- SWRVWNJARPMWAG-QFIPXVFZSA-N 4-(1-tert-butyl-2-methylimidazo[4,5-b]pyridin-6-yl)-N-[5-[[(3S)-4-ethyl-3-(methoxymethyl)piperazin-1-yl]methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H](N(CC1)CC)COC)C SWRVWNJARPMWAG-QFIPXVFZSA-N 0.000 description 1
- QMHXVMTZJOCDCD-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoro-N-[5-(morpholin-4-ylmethyl)pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCOCC1)C QMHXVMTZJOCDCD-UHFFFAOYSA-N 0.000 description 1
- LKMPYLLZFKBUOG-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoro-N-[5-[(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)C)C LKMPYLLZFKBUOG-UHFFFAOYSA-N 0.000 description 1
- LYYXBYJBHRDCMU-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoro-N-[5-[1-(4-methylpiperazin-1-yl)ethyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)C(C)N1CCN(CC1)C)C LYYXBYJBHRDCMU-UHFFFAOYSA-N 0.000 description 1
- XIUPOZDEVDGCIG-BGYRXZFFSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoro-N-[5-[[(1R,5S)-8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl]methyl]pyridin-2-yl]pyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H]2CC[C@@H](C1)N2C)C XIUPOZDEVDGCIG-BGYRXZFFSA-N 0.000 description 1
- GYJSPJBFUCHAPW-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-N-[5-(3,8-diazabicyclo[3.2.1]octan-8-ylmethyl)pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C12CNCC(CC1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)(C)C)C)F GYJSPJBFUCHAPW-UHFFFAOYSA-N 0.000 description 1
- ULWUJVPFWJEXFU-UHFFFAOYSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-N-[5-[1-(4-ethylpiperazin-1-yl)ethyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)C(C)N1CCN(CC1)CC)C ULWUJVPFWJEXFU-UHFFFAOYSA-N 0.000 description 1
- HFAFEBQJKWPTGR-KDURUIRLSA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-N-[5-[[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound [C@H]12CN(C[C@H](CC1)N2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)(C)C)C)F HFAFEBQJKWPTGR-KDURUIRLSA-N 0.000 description 1
- AJFISQCHDCKCCG-OYRHEFFESA-N 4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-N-[5-[[(1R,5S)-8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl]methyl]pyridin-2-yl]-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@H]2CC[C@@H](C1)N2CC)C AJFISQCHDCKCCG-OYRHEFFESA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- UKNYSJCAGUXDOQ-UHFFFAOYSA-N 5-bromo-2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CN=C1Cl UKNYSJCAGUXDOQ-UHFFFAOYSA-N 0.000 description 1
- ZGDXHNOMOPXROH-UHFFFAOYSA-N 5-bromo-3-tert-butyl-1-methylpyrazolo[3,4-b]pyridine Chemical compound BrC1=CN=C2N(C)N=C(C(C)(C)C)C2=C1 ZGDXHNOMOPXROH-UHFFFAOYSA-N 0.000 description 1
- YRGMYJUKFJPNPD-UHFFFAOYSA-N 5-bromopyridine-2,3-diamine Chemical compound NC1=CC(Br)=CN=C1N YRGMYJUKFJPNPD-UHFFFAOYSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- IUPWWIRRDLBAIX-UHFFFAOYSA-N 5-fluoro-N-[5-[(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CN(CC2C1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C IUPWWIRRDLBAIX-UHFFFAOYSA-N 0.000 description 1
- DAGFXCKWWJZPBO-UHFFFAOYSA-N 5-fluoro-N-[5-[(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CN(CC2C1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C DAGFXCKWWJZPBO-UHFFFAOYSA-N 0.000 description 1
- YBVKJCABYASGDY-UHFFFAOYSA-N 5-fluoro-N-[5-[(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)sulfonyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)S(=O)(=O)N1CC2CN(CC2C1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C YBVKJCABYASGDY-UHFFFAOYSA-N 0.000 description 1
- NJTPWWGECXFCBP-UHFFFAOYSA-N 5-fluoro-N-[5-[(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)sulfonyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)S(=O)(=O)N1CC2CN(CC2C1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C NJTPWWGECXFCBP-UHFFFAOYSA-N 0.000 description 1
- GALNGZKEUUMJNC-UHFFFAOYSA-N 5-fluoro-N-[5-[(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C GALNGZKEUUMJNC-UHFFFAOYSA-N 0.000 description 1
- MTLRQTGOJJGTHS-UHFFFAOYSA-N 5-fluoro-N-[5-[(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C2CN(CC1CC2)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C MTLRQTGOJJGTHS-UHFFFAOYSA-N 0.000 description 1
- UQZNVWOFBPGCSJ-UHFFFAOYSA-N 5-fluoro-N-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-4-(1-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CCN(CC1)C)C=1C=C2C(=NC=1)N(N=C2C(C)C)C UQZNVWOFBPGCSJ-UHFFFAOYSA-N 0.000 description 1
- DOWXRMYLEIDUDR-UHFFFAOYSA-N 5-fluoro-N-[5-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CCC(C1)N2C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C DOWXRMYLEIDUDR-UHFFFAOYSA-N 0.000 description 1
- VDUVGRFURLVFQC-UHFFFAOYSA-N 5-fluoro-N-[5-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CCC(C1)N2C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C VDUVGRFURLVFQC-UHFFFAOYSA-N 0.000 description 1
- ZNXVJYHKGLYXNQ-UHFFFAOYSA-N 5-fluoro-N-[5-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)sulfonyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)S(=O)(=O)N1CC2CCC(C1)N2C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C ZNXVJYHKGLYXNQ-UHFFFAOYSA-N 0.000 description 1
- COYZXCDVMVJKCQ-UHFFFAOYSA-N 5-fluoro-N-[5-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)sulfonyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)S(=O)(=O)N1CC2CCC(C1)N2C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C COYZXCDVMVJKCQ-UHFFFAOYSA-N 0.000 description 1
- HEKOJWHQLPOFJN-PMACEKPBSA-N 5-fluoro-N-[5-[[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1[C@@H]2CN([C@H](C1)C2)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C HEKOJWHQLPOFJN-PMACEKPBSA-N 0.000 description 1
- VWBWHIPJAAPDJH-GOSISDBHSA-N 5-fluoro-N-[5-[[(2R)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1[C@@H](CN(CC1)C1COC1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C VWBWHIPJAAPDJH-GOSISDBHSA-N 0.000 description 1
- WMAYRLPSSAQOIE-GOSISDBHSA-N 5-fluoro-N-[5-[[(2R)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1[C@@H](CN(CC1)C1COC1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C WMAYRLPSSAQOIE-GOSISDBHSA-N 0.000 description 1
- WMAYRLPSSAQOIE-SFHVURJKSA-N 5-fluoro-N-[5-[[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1[C@H](CN(CC1)C1COC1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C WMAYRLPSSAQOIE-SFHVURJKSA-N 0.000 description 1
- YPTGIKFVDJSLSX-GOSISDBHSA-N 5-fluoro-N-[5-[[(3R)-3-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C[C@H](N(CC1)C1COC1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C YPTGIKFVDJSLSX-GOSISDBHSA-N 0.000 description 1
- ACFOBWPAKSXGEZ-SFHVURJKSA-N 5-fluoro-N-[5-[[(3S)-3-methyl-4-(oxetan-3-yl)piperazin-1-yl]methyl]pyridin-2-yl]-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1C[C@@H](N(CC1)C1COC1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C ACFOBWPAKSXGEZ-SFHVURJKSA-N 0.000 description 1
- WEGQAYVHXXNNIF-UHFFFAOYSA-N 6-ethyl-N-[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]-7,8-dihydro-5H-1,6-naphthyridin-2-amine Chemical compound C(C)N1CC=2C=CC(=NC=2CC1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F WEGQAYVHXXNNIF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ALGGPCBCKOVRKZ-UHFFFAOYSA-N 8-ethyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2CC ALGGPCBCKOVRKZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- PATURKMKEJRUNW-UHFFFAOYSA-N C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C2=NC(=NC=C2Cl)NC2=NC=C(C=C2)CN2CC=NC=C2)C Chemical compound C(C)(C)(C)N1C(=NC2=NC=C(C=C21)C2=NC(=NC=C2Cl)NC2=NC=C(C=C2)CN2CC=NC=C2)C PATURKMKEJRUNW-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- GFYJLRABYLIFPC-UHFFFAOYSA-N FC=1C(=NC(=NC1)NC1=CC=C(C=N1)C=O)C=1C=C2C(=NC1)N=C(N2C(C)C)C Chemical compound FC=1C(=NC(=NC1)NC1=CC=C(C=N1)C=O)C=1C=C2C(=NC1)N=C(N2C(C)C)C GFYJLRABYLIFPC-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- JGZZHITWESAREC-UHFFFAOYSA-N Ic1ccc(CNCC2)c2n1 Chemical compound Ic1ccc(CNCC2)c2n1 JGZZHITWESAREC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 241000713321 Intracisternal A-particles Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- SRLUIDXAEQPJQZ-UHFFFAOYSA-N N-[4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoropyrimidin-2-yl]-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=2CCNCC=2C=C1)C SRLUIDXAEQPJQZ-UHFFFAOYSA-N 0.000 description 1
- ZDCKMDPDIVZCQN-UHFFFAOYSA-N N-[4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoropyrimidin-2-yl]-6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=2CCN(CC=2C=C1)C)C ZDCKMDPDIVZCQN-UHFFFAOYSA-N 0.000 description 1
- PKGAMDKFYPRURD-UHFFFAOYSA-N N-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CNCC2C1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C PKGAMDKFYPRURD-UHFFFAOYSA-N 0.000 description 1
- OTBGCTYDRYXMLZ-UHFFFAOYSA-N N-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)CN1CC2CNCC2C1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C OTBGCTYDRYXMLZ-UHFFFAOYSA-N 0.000 description 1
- MKJWHEGWDHSUKW-UHFFFAOYSA-N N-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrol-5-ylsulfonyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=C1)S(=O)(=O)N1CC2CNCC2C1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C MKJWHEGWDHSUKW-UHFFFAOYSA-N 0.000 description 1
- FRKDAHHJAVSESV-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-3-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C12CN(CC(CC1)N2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F FRKDAHHJAVSESV-UHFFFAOYSA-N 0.000 description 1
- QNASYWIEJBZBTH-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-3-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C12CN(CC(CC1)N2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F QNASYWIEJBZBTH-UHFFFAOYSA-N 0.000 description 1
- VTBGFCFOXPCDNC-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-3-ylsulfonyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C12CN(CC(CC1)N2)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F VTBGFCFOXPCDNC-UHFFFAOYSA-N 0.000 description 1
- HIUKIJAVMAMNRK-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-3-ylsulfonyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C12CN(CC(CC1)N2)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F HIUKIJAVMAMNRK-UHFFFAOYSA-N 0.000 description 1
- GDYQWMGEUNBKHG-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-8-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C12CNCC(CC1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F GDYQWMGEUNBKHG-UHFFFAOYSA-N 0.000 description 1
- SVFUBMXEHZHPKF-UHFFFAOYSA-N N-[5-(3,8-diazabicyclo[3.2.1]octan-8-ylmethyl)pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C12CNCC(CC1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F SVFUBMXEHZHPKF-UHFFFAOYSA-N 0.000 description 1
- NYPBIQUVKPUVMJ-UHFFFAOYSA-N N-[5-(4-ethylpiperazin-1-yl)sulfonylpyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1CCN(CC1)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F NYPBIQUVKPUVMJ-UHFFFAOYSA-N 0.000 description 1
- NSFRAHQIAILLSA-UHFFFAOYSA-N N-[5-[(2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2C(C1)CN(C2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F NSFRAHQIAILLSA-UHFFFAOYSA-N 0.000 description 1
- XTMMVHHPRCSAQQ-UHFFFAOYSA-N N-[5-[(2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2C(C1)CN(C2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F XTMMVHHPRCSAQQ-UHFFFAOYSA-N 0.000 description 1
- JRLVHJNTMJUXPV-UHFFFAOYSA-N N-[5-[(2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)sulfonyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2C(C1)CN(C2)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F JRLVHJNTMJUXPV-UHFFFAOYSA-N 0.000 description 1
- UQNZITBETGUIJA-UHFFFAOYSA-N N-[5-[(2-ethyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)sulfonyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2C(C1)CN(C2)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F UQNZITBETGUIJA-UHFFFAOYSA-N 0.000 description 1
- SGAIWXGJMYYUCY-UHFFFAOYSA-N N-[5-[(3-ethyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2CCC(C1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F SGAIWXGJMYYUCY-UHFFFAOYSA-N 0.000 description 1
- HQRCDDDJXIIDKH-UHFFFAOYSA-N N-[5-[(3-ethyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1CC2CCC(C1)N2CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F HQRCDDDJXIIDKH-UHFFFAOYSA-N 0.000 description 1
- NTOMUIPJWWSMJA-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(1-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1CCN(CC1)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N(N=C2C(C)C)C)F NTOMUIPJWWSMJA-UHFFFAOYSA-N 0.000 description 1
- KKAQRYFELLGYJF-UHFFFAOYSA-N N-[5-[(8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1C2CN(CC1CC2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F KKAQRYFELLGYJF-UHFFFAOYSA-N 0.000 description 1
- SUPJWIISFGJSIP-UHFFFAOYSA-N N-[5-[(8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-amine Chemical compound C(C)N1C2CN(CC1CC2)CC=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC=2C(N=C1)=NN(C=2C(C)C)C)F SUPJWIISFGJSIP-UHFFFAOYSA-N 0.000 description 1
- OHQTVVOGIIRXNP-UHFFFAOYSA-N N-[5-[(8-ethyl-3,8-diazabicyclo[3.2.1]octan-3-yl)sulfonyl]pyridin-2-yl]-5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-amine Chemical compound C(C)N1C2CN(CC1CC2)S(=O)(=O)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C)F OHQTVVOGIIRXNP-UHFFFAOYSA-N 0.000 description 1
- CKERNBMDYQJBJT-HXUWFJFHSA-N N-[5-[[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]methyl]pyridin-2-yl]-4-(3-tert-butyl-2-methylpyrazolo[3,4-b]pyridin-5-yl)-5-fluoropyrimidin-2-amine Chemical compound C(C)(C)(C)C=1N(N=C2N=CC(=CC2=1)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1C[C@@H]2N(CC1)CCC2)C CKERNBMDYQJBJT-HXUWFJFHSA-N 0.000 description 1
- YUVAXBUOGGOKTC-UHFFFAOYSA-N N-[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=2CCNCC=2C=C1)C=1C=C2C(=NC=1)N=C(N2C(C)C)C YUVAXBUOGGOKTC-UHFFFAOYSA-N 0.000 description 1
- BWOFAGGSBDGUBK-UHFFFAOYSA-N N-[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]-6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=2CCN(CC=2C=C1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C BWOFAGGSBDGUBK-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MBKMCBQLIZVKGG-KZUDCZAMSA-N OC(N1[C@@H](CC2=CC=CC=C2)C(CCC2)N2CC1)=O Chemical compound OC(N1[C@@H](CC2=CC=CC=C2)C(CCC2)N2CC1)=O MBKMCBQLIZVKGG-KZUDCZAMSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- MIAHFULQHQHVKY-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CN(CC2C1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C MIAHFULQHQHVKY-UHFFFAOYSA-N 0.000 description 1
- SHSPUWCKPBMEPG-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CCN(CC1)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C SHSPUWCKPBMEPG-UHFFFAOYSA-N 0.000 description 1
- NTUNQVNRPCWODX-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CCC(C1)N2C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C NTUNQVNRPCWODX-UHFFFAOYSA-N 0.000 description 1
- OIXJJHPWGOLKOI-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CN(CC2C1)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C OIXJJHPWGOLKOI-UHFFFAOYSA-N 0.000 description 1
- GCVGXNPYADFONH-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1C2CN(CC1CC2)C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C GCVGXNPYADFONH-UHFFFAOYSA-N 0.000 description 1
- LLVXWLYIXHSNFK-UHFFFAOYSA-N [6-[[5-fluoro-4-(2-methyl-3-propan-2-ylpyrazolo[3,4-b]pyridin-5-yl)pyrimidin-2-yl]amino]pyridin-3-yl]-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methanone Chemical compound FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)C(=O)N1CC2CCC(C1)N2C)C1=CC=2C(N=C1)=NN(C=2C(C)C)C LLVXWLYIXHSNFK-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical group C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical group C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical group C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical group C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- TUCBIILSAIXHOQ-UHFFFAOYSA-N ethyl 2-aminoacetate;2,2,2-trifluoroacetic acid Chemical compound CCOC(=O)CN.OC(=O)C(F)(F)F TUCBIILSAIXHOQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- KJDJPXUIZYHXEZ-UHFFFAOYSA-N hydrogen sulfate;methylaminoazanium Chemical compound CN[NH3+].OS([O-])(=O)=O KJDJPXUIZYHXEZ-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000005404 monopole Effects 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000014500 neuronal tumor Diseases 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 208000012972 squamous cell carcinoma of colon Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GZVYQUVSTREGTR-VXKWHMMOSA-N tert-butyl (1S,4S)-5-[[6-[[5-fluoro-4-(2-methyl-1-propan-2-ylimidazo[4,5-b]pyridin-6-yl)pyrimidin-2-yl]amino]pyridin-3-yl]methyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical group FC=1C(=NC(=NC=1)NC1=CC=C(C=N1)CN1[C@@H]2CN([C@H](C1)C2)C(=O)OC(C)(C)C)C=1C=C2C(=NC=1)N=C(N2C(C)C)C GZVYQUVSTREGTR-VXKWHMMOSA-N 0.000 description 1
- UXAWXZDXVOYLII-YUMQZZPRSA-N tert-butyl (1s,4s)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1[C@@H]2N(C(=O)OC(C)(C)C)C[C@H]1NC2 UXAWXZDXVOYLII-YUMQZZPRSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical group C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292259P | 2016-02-06 | 2016-02-06 | |
| US62/292,259 | 2016-02-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201801729A TW201801729A (zh) | 2018-01-16 |
| TWI736578B true TWI736578B (zh) | 2021-08-21 |
Family
ID=59500239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106103864A TWI736578B (zh) | 2016-02-06 | 2017-02-06 | 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN108602799B (fr) |
| TW (1) | TWI736578B (fr) |
| WO (1) | WO2017133701A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107337634B (zh) * | 2017-08-28 | 2019-07-09 | 新发药业有限公司 | 一种阿贝西利中间体化合物的制备方法 |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. | キナーゼ阻害剤としての複素環式化合物 |
| GEP20227433B (en) | 2018-04-26 | 2022-10-25 | Pfizer | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| MX2021000895A (es) | 2018-07-27 | 2021-08-24 | California Inst Of Techn | Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos. |
| MA55909A (fr) * | 2019-05-05 | 2022-03-16 | Qilu Regor Therapeutics Inc | Inhibiteurs de cdk |
| CN111303128B (zh) * | 2020-04-07 | 2020-10-27 | 苏州信诺维医药科技有限公司 | 一种多环类化合物、其制备方法及应用 |
| US11685744B2 (en) | 2020-09-21 | 2023-06-27 | Prelude Therapeutics Incorporated | CDK inhibitors and their use as pharmaceuticals |
| WO2022113003A1 (fr) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Inhibiteurs de cdk |
| WO2022149057A1 (fr) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Inhibiteurs de cdk |
| CA3245813A1 (fr) * | 2022-03-23 | 2023-09-28 | Prelude Therapeutics, Incorporated | Composés polymorphes et leurs utilisations |
| KR20250002427A (ko) * | 2022-04-08 | 2025-01-07 | 바이오렉시스 테라퓨틱스, 인크. | Cdk9 억제제 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102264725A (zh) * | 2008-12-22 | 2011-11-30 | 伊莱利利公司 | 蛋白激酶抑制剂 |
| WO2016014904A1 (fr) * | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | Dérivés de 2-h-indazole en tant qu'inhibiteurs de la kinase dépendante de la cycline (cdk) et leurs utilisations thérapeutiques |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2654670A1 (fr) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Nouveaux composes |
| US9796701B2 (en) * | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| WO2016015605A1 (fr) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations |
| CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
| CN105111191B (zh) * | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
-
2017
- 2017-02-06 WO PCT/CN2017/072958 patent/WO2017133701A1/fr not_active Ceased
- 2017-02-06 CN CN201780010075.XA patent/CN108602799B/zh not_active Expired - Fee Related
- 2017-02-06 TW TW106103864A patent/TWI736578B/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102264725A (zh) * | 2008-12-22 | 2011-11-30 | 伊莱利利公司 | 蛋白激酶抑制剂 |
| WO2016014904A1 (fr) * | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | Dérivés de 2-h-indazole en tant qu'inhibiteurs de la kinase dépendante de la cycline (cdk) et leurs utilisations thérapeutiques |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017133701A1 (fr) | 2017-08-10 |
| CN108602799A (zh) | 2018-09-28 |
| CN108602799B (zh) | 2021-08-03 |
| TW201801729A (zh) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI736578B (zh) | 6-5元稠合唑環衍生物及其藥物組合物,以及作為藥物的應用 | |
| JP7535537B2 (ja) | タンパク質キナーゼ阻害剤としての置換ピロロ[2,3-b]ピリジン及びピラゾロ[3,4-b]ピリジン誘導体 | |
| EP3765462B1 (fr) | Composés de (2-azabicyclo [3.1.0] hexan-2-yl) pyrazolo [1, 5-a] pyrimidine et imidazo [1, 2-b] pyridazine substitués en tant qu'inhibiteurs de kinases trk | |
| CN115551856A (zh) | 作为cdk2/4/6抑制剂的化合物 | |
| CN111971287A (zh) | 作为trk激酶抑制剂的大环化合物 | |
| TW202144357A (zh) | 作為激酶抑制劑的化合物 | |
| TW202028209A (zh) | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 | |
| JP6927548B2 (ja) | ある種のタンパク質キナーゼ阻害剤 | |
| WO2021047584A1 (fr) | Composés de (2-azabicyclo [3.1.0] hexan-2-yl) pyrazolo [1, 5-a] pyrimidine et imidazo [1, 2-b] pyridazine substitués utilisés comme inhibiteurs de kinases trk | |
| TWI791444B (zh) | 作為激酶抑制劑的取代的吡咯并[2,3-d]噠嗪-4-酮和吡唑并[3,4-d]噠嗪-4-酮 | |
| JP2023549273A (ja) | プロテインキナ-ゼ阻害剤としての置換されたピロロ[2,3-b]ピリジン及びピラゾロ[3,4-b]ピリジン誘導体 | |
| TW202017927A (zh) | 作爲RET激酶抑制劑的取代的[1,2,4]三唑[1,5-a]吡啶化合物 | |
| TWI827869B (zh) | 作為蛋白激酶抑制劑的取代的吡咯並[2,3-b]吡啶及吡唑並[3,4-b]吡啶衍生物 | |
| RU2778294C2 (ru) | Макроциклические соединения как ингибиторы киназ trk | |
| TW202028199A (zh) | 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物 | |
| CN115605481A (zh) | 作为激酶抑制剂的化合物 | |
| HK40034411A (en) | Substituted (2-azabicyclo [3.1.0] hexan-2-yl) pyrazolo [1, 5-a] pyrimidine and imidazo [1, 2-b] pyridazine compounds as trk kinases inhibitors | |
| HK40034417A (en) | Macrocyclic compounds as trk kinases inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |